• AZD1390: Ultra-Potent ATM Kinase Inhibitor for DNA Repair St

  2026-07-29

  AZD1390 is a highly selective ATM kinase inhibitor that enables precise interrogation of DNA double-strand break repair and cell cycle regulation in cancer research. It delivers sub-nanomolar potency, especially in radiosensitizing glioma and lung cancer cells. Validated in cellular and in vivo models, AZD1390 advances mechanistic studies and translational workflows.

• 1,2-Dioleoyl-3-trimethylammonium-propane Chloride in Precisi

  2026-07-29

  DOTAP empowers high-efficiency nucleic acid delivery across gene expression, functional genomics, and immunometabolic modulation workflows. This article dissects practical protocol enhancements and troubleshooting insights, spotlighting how innovations from metabolic nanodelivery research elevate applied gene modulation.

• SCH772984: Precision ERK1/2 Inhibition for Tumor Radiosensit

  2026-07-28

  Explore how SCH772984, a selective ERK1/2 inhibitor, advances MAPK/ERK pathway research and tumor radiosensitivity studies. This article offers a unique, in-depth analysis of its mechanistic role, with insights beyond current literature.

• SCH772984: ERK1/2 Inhibitor Protocols for Tumor Radiosensiti

  2026-07-28

  SCH772984 offers precise MAPK/ERK pathway inhibition, making it a cornerstone for dissecting radioresistance mechanisms in mutant-driven cancers. This guide delivers actionable experimental protocols, troubleshooting insights, and translational perspectives for integrating SCH772984 into advanced cell and xenograft models.

• Sustained VX-770 Potentiation of CFTR in Primary Airway Epit

  2026-07-27

  This study rigorously demonstrates that even brief, low-concentration exposures to VX-770 (ivacaftor) can produce a persistent potentiation of CFTR channel activity in human airway epithelial cultures. The findings provide new insights into the pharmacodynamics of CFTR modulators and have direct implications for both experimental designs and clinical management of cystic fibrosis.

• Y-27632 Dihydrochloride: Applied Workflows in ROCK Inhibitio

  2026-07-27

  Unlock rigorous, reproducible cytoskeletal and cancer research with Y-27632 dihydrochloride, a selective ROCK inhibitor trusted for cell viability and invasion assays. This practical guide translates recent experimental evidence into actionable workflows and troubleshooting strategies, empowering researchers to maximize data quality and insight.

• Vemurafenib (PLX4032): Decoding Resistance in Melanoma Resea

  2026-07-26

  Explore how Vemurafenib (PLX4032) enables next-generation melanoma research by dissecting resistance networks and signaling rewiring, with a focus on recent multi-omics insights. This article offers advanced guidance for assay design and resistance modeling using Vemurafenib.

• Nanoplastic Exposure Disrupts Vascular Lipid Metabolism via

  2026-07-25

  This study demonstrates that prenatal and lactational exposure to polystyrene nanoplastics (PS-NPs) leads to lipid accumulation in vascular smooth muscle cells of male offspring, driven by the MAPK/ERK/UHRF1 signaling pathway. The findings provide mechanistic insight into how environmental nanoplastics exposure can affect early vascular health and highlight the utility of MEK inhibitors in dissecting these pathways.

• Hydroxytyrosol in Research: Protocol Precision & Workflow Ex

  2026-07-24

  Hydroxytyrosol, a potent 4-(2-hydroxyethyl)benzene-1,2-diol, is redefining cardiovascular and inflammation research with exceptional antioxidant reliability and workflow flexibility. This article delivers stepwise guidance, troubleshooting mastery, and cross-study optimization strategies—empowering research teams to achieve reproducible, high-impact results.

• AG-120 (Ivosidenib) Workflows: Precision in Mutant IDH1 AML

  2026-07-24

  AG-120 (Ivosidenib) empowers researchers to dissect metabolic rewiring and differentiation blockade in mutant IDH1 acute myeloid leukemia. This article delivers bench-tested workflows, troubleshooting strategies, and actionable insights for optimizing 2-hydroxyglutarate reduction and myeloid differentiation assays.

• Angiotensin II–HIF-1α-HILPDA Axis Drives Radioresistance in

  2026-07-23

  This study reveals that local angiotensin II suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma (NPC) via the HIF-1α-HILPDA axis. The mechanistic insights highlight therapeutic targets and biomarkers, proposing dual inhibition of Ang II signaling and ferroptosis modulation to enhance NPC radiosensitivity.

• GST Inhibition Reveals Mechanisms of Insecticide Resistance

  2026-07-23

  The reference study demonstrates that glutathione S-transferase (GST) activity is central to the resistance of Megalurothrips usitatus against the pyrethroid insecticide lambda-cyhalothrin. Inhibiting GST with diethyl maleate decreased antioxidant defenses and dramatically increased insecticide sensitivity, offering mechanistic insight for resistance management and oxidative stress modeling.

• Aromatase Inhibition by Lamotrigine: Impacts on Steroidogene

  2026-07-22

  This study systematically investigates how lamotrigine and other antiepileptic drugs inhibit the human aromatase enzyme (CYP19), a key regulator of sex hormone synthesis. The findings provide detailed evidence of lamotrigine’s moderate inhibitory effect, with implications for endocrine health in epilepsy treatment and experimental research.

• Applied Use-Cases of (S)-1-(3-fluoro-4-(trifluoromethoxy)phe

  2026-07-22

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) empowers researchers to dissect the Nrf2 signaling axis and osteoclast differentiation with high reproducibility. Its robust solubility and validated purity underpin advanced enzyme inhibition and redox studies in biochemical, cancer, and neuroscience research.

• UL84-FHL2 Axis in HCMV: Suppressing Interferon and Promoting

  2026-07-21

  Li et al. (2026) identify a novel immune evasion mechanism in human cytomegalovirus (HCMV), showing that the viral UL84 protein binds FHL2 to inhibit type I interferon (IFN-β) production and enhance viral replication. This discovery advances understanding of HCMV pathogenesis and opens avenues for targeting viral-host protein interactions.

16842 records 1/1123 page Next 12345 下5页 Last page